Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma

Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma

JUPITER, Fla., Oct. 22, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for…